Skip to main content

Biogen quits controversial Alzheimer's drug Aduhelm

By The Wall Street Journal  
   January 31, 2024

The biotech says it will focus on advancing a newer Alzheimer's medicine, developing others.

Full story


Get the latest on healthcare leadership in your inbox.